Lilly Asia Ventures — 2024 Investments
1 investments dated 2024 · listed companies and verified rows first · show all
Comanche Biopharmacomanchebiopharma.cominJan 2024 · $75M
Comanche Biopharma is a biopharmaceutical company developing an investigational siRNA medicine (CBP-4888) targeting a root cause of preterm preeclampsia in pregnant women.
BiotechFemTechHealthtechConcord, US
Mike Young(Founder)T Scott Johnson(Founder)inPaul Antinori(Executive Officer)Allison August(Executive Officer)Michael Young(Executive Officer)Thomas Scott Johnson(Executive Officer, Director)
Co-investorsAtlas VentureGV (Google Ventures)Broadview VenturesF-Prime CapitalNew Enterprise Associates (NEA)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.